Literature DB >> 29174592

Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects.

Thu Ha Pham1, Céline Defaix1, Xiaoming Xu2, Shi-Xian Deng2, Nicolas Fabresse3, Jean-Claude Alvarez3, Donald W Landry2, Rebecca A Brachman4, Christine A Denny5, Alain M Gardier6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29174592     DOI： 10.1016/j.biopsych.2017.10.020

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  44 in total

1.  Hydroxynorketamine Blocks N-Methyl-d-Aspartate Receptor Currents by Binding to Closed Receptors.

Authors:  Jamie A Abbott; Gabriela K Popescu
Journal:  Mol Pharmacol       Date:  2020-06-29       Impact factor: 4.436

2.  Pharmaco-electroencephalographic responses in the rat differ between active and inactive locomotor states.

Authors:  Ingeborg H Hansen; Claus Agerskov; Lars Arvastson; Jesper F Bastlund; Helge B D Sørensen; Kjartan F Herrik
Journal:  Eur J Neurosci       Date:  2019-04-01       Impact factor: 3.386

3.  Ketamine increases vmPFC activity: Effects of (R)- and (S)-stereoisomers and (2R,6R)-hydroxynorketamine metabolite.

Authors:  Brendan D Hare; Santosh Pothula; Ralph J DiLeone; Ronald S Duman
Journal:  Neuropharmacology       Date:  2020-01-09       Impact factor: 5.250

Review 4.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 5.  Ketamine: The final frontier or another depressing end?

Authors:  Omar K Sial; Eric M Parise; Lyonna F Parise; Tamara Gnecco; Carlos A Bolaños-Guzmán
Journal:  Behav Brain Res       Date:  2020-02-01       Impact factor: 3.332

Review 6.  Esketamine: a glimmer of hope in treatment-resistant depression.

Authors:  Upinder Kaur; Bhairav Kumar Pathak; Amit Singh; Sankha Shubhra Chakrabarti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-11-19       Impact factor: 5.270

Review 7.  Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.

Authors:  Jaclyn N Highland; Panos Zanos; Lace M Riggs; Polymnia Georgiou; Sarah M Clark; Patrick J Morris; Ruin Moaddel; Craig J Thomas; Carlos A Zarate; Edna F R Pereira; Todd D Gould
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 8.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

Review 9.  Mechanisms of ketamine action as an antidepressant.

Authors:  P Zanos; T D Gould
Journal:  Mol Psychiatry       Date:  2018-03-13       Impact factor: 15.992

10.  Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine.

Authors:  Jaclyn N Highland; Patrick J Morris; Panos Zanos; Jacqueline Lovett; Soumita Ghosh; Amy Q Wang; Carlos A Zarate; Craig J Thomas; Ruin Moaddel; Todd D Gould
Journal:  J Psychopharmacol       Date:  2018-11-29       Impact factor: 4.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.